317 related articles for article (PubMed ID: 28467330)
1. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management.
Maconi G
Acta Biomed; 2017 Apr; 88(1):25-32. PubMed ID: 28467330
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy: rifaximin-α and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease.
Pietrzak AM; Banasiewicz T; Skoczylas K; Dziki A; Szczepkowski M
Pol Przegl Chir; 2020 Apr; 92(2):22-28. PubMed ID: 32312914
[TBL] [Abstract][Full Text] [Related]
3. Rationale and evidences for treatment of symptomatic uncomplicated diverticular disease.
Cuomo R; Cargiolli M; Andreozzi P; Zito FP; Sarnelli G
Minerva Gastroenterol Dietol; 2017 Jun; 63(2):130-142. PubMed ID: 27973463
[TBL] [Abstract][Full Text] [Related]
4. Cyclic rifaximin therapy effectively prevents the recurrence of symptoms after exacerbation of symptomatic uncomplicated diverticular disease: a retrospective study.
Pietrzak AM; Dziki A; Banasiewicz T; Reguła J
Prz Gastroenterol; 2019; 14(1):69-78. PubMed ID: 30944680
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon.
Di Mario F; Miraglia C; Cambiè G; Violi A; Nouvenne A; Franceschi M; Brandimarte G; Elisei W; Picchio M; Tursi A
J Investig Med; 2019 Apr; 67(4):767-770. PubMed ID: 30593541
[TBL] [Abstract][Full Text] [Related]
6. Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches.
Alamo RZ; Quigley EMM
Curr Opin Gastroenterol; 2019 Jan; 35(1):27-33. PubMed ID: 30407258
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of symptomatic uncomplicated diverticular disease could be lower than expected: a single-center colonoscopy-based cohort study.
Tursi A; Elisei W; Franceschi M; Picchio M; Di Mario F; Brandimarte G
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e478-e483. PubMed ID: 33867449
[TBL] [Abstract][Full Text] [Related]
8. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting.
Tursi A; Elisei W; Picchio M; Giorgetti GM; Brandimarte G
J Clin Gastroenterol; 2015 Mar; 49(3):218-21. PubMed ID: 24583746
[TBL] [Abstract][Full Text] [Related]
9. Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons.
Brandimarte G; Bafutto M; Kruis W; Scarpignato C; Mearin F; Barbara G; Štimac D; Vranić L; Cassieri C; Lecca PG; D'Avino A; Malfertheiner P
J Gastrointestin Liver Dis; 2019 Dec; 28(suppl. 4):23-29. PubMed ID: 31930227
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined prophylactic therapy (rifaximine alpha + prebiotic arabinogalactan with lactofferin) on GUT function in patients with diagnosed symptomatic uncomplicated diverticular disease.
Banasiewicz T; Paszkowski J; Borejsza-Wysocki M; Bobkiewicz A; Pietrzak A; Szczepkowski M; Francuzik W
Pol Przegl Chir; 2019 Aug; 91(4):1-8. PubMed ID: 31481638
[No Abstract] [Full Text] [Related]
11. General practitioners' management of symptomatic uncomplicated diverticular disease of the colon by using rifaximin, a non-adsorbable antibiotic.
De Bastiani R; Sanna G; Bertolusso L; Casella G; De Polo M; Zamparella M; Cottone C; Tosetti C; Mancuso M; Pirrotta E; Lanzarotto L; Napoli L; De Bastiani M; Disclafani G; Gambaro P; Scoglio R; Belvedere A; Fasulo S; D'Urso M; Benedetto E; Baldi E; Marchesan F; Abagnale G; Turnava L; Salomè E; Ingravalle F; Tursi A
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):423-430. PubMed ID: 33506932
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic challenges of symptomatic uncomplicated diverticular disease.
Cremon C; Bellacosa L; Barbaro MR; Cogliandro RF; Stanghellini V; Barbara G
Minerva Gastroenterol Dietol; 2017 Jun; 63(2):119-129. PubMed ID: 28079347
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic Uncomplicated Diverticular Disease (SUDD): Practical Guidance and Challenges for Clinical Management.
Calini G; Abd El Aziz MA; Paolini L; Abdalla S; Rottoli M; Mari G; Larson DW
Clin Exp Gastroenterol; 2023; 16():29-43. PubMed ID: 37013200
[TBL] [Abstract][Full Text] [Related]
15. Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study.
Ivashkin V; Shifrin O; Maslennikov R; Poluektova E; Korolev A; Kudryavtseva A; Krasnov G; Benuni N; Barbara G
BMC Gastroenterol; 2023 Mar; 23(1):82. PubMed ID: 36959568
[TBL] [Abstract][Full Text] [Related]
16. [Diverticular disease: treatment and management by general practitioners in Germany - high importance of probiotics in primary care].
Gross M; Beckenbauer UE; Bruder L; Zehrer A
MMW Fortschr Med; 2022 Dec; 164(Suppl 8):16-26. PubMed ID: 36520376
[TBL] [Abstract][Full Text] [Related]
17. The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a "real-life" study.
Moniuszko A; Rydzewska G
Prz Gastroenterol; 2017; 12(2):145-151. PubMed ID: 28702105
[TBL] [Abstract][Full Text] [Related]
18. Diverticular Disease: An Update on Pathogenesis and Management.
Rezapour M; Ali S; Stollman N
Gut Liver; 2018 Mar; 12(2):125-132. PubMed ID: 28494576
[TBL] [Abstract][Full Text] [Related]
19. Course of the Diverticular Disease: What is changing?
Milosavljeviĉ T; Brandimarte G; Stollman N; Barbara G; Lahat A; Scarpignato C; Lanas A; Papa V; Tursi A; Nardone G
J Gastrointestin Liver Dis; 2019 Dec; 28(suppl. 4):11-16. PubMed ID: 31930229
[TBL] [Abstract][Full Text] [Related]
20. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.
Schey R; Rao SS
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
